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ABSTRACT: A three-dimensional structure comparison between the dimeric regulatory serine-binding domain
of Escherichia coli D-3-phosphoglycerate dehydrogenase [Schuller, D. J., Grant, G. A., and Banaszak, L.
J. (1995) Nat. Struct. Biol. 2, 69-76] and the regulatory domain of E. coli threonine deaminase [Gallagher,
D. T., Gilliland, G. L., Xiao, G., Zondlo, J., Fisher, K. E., Chinchilla, D., and Eisenstein, E. (1998) Structure
6, 465-475] led us to make the hypothesis that threonine deaminase could have two binding sites per
monomer. To test this hypothesis about the corresponding plant enzyme, site-directed mutagenesis was
carried out on the recombinant Arabidopsis thaliana threonine deaminase. Kinetic and binding experiments
demonstrated for the first time that each regulatory domain of the monomers of A. thaliana threonine
deaminase possesses two different effector-binding sites constituted in part by Y449 and Y543. Our results
demonstrate that Y449 belongs to a high-affinity binding site whose interaction with a first isoleucine
induces conformational modifications yielding a conformer displaying a higher activity and with enhanced
ability to bind a second isoleucine on a lower-affinity binding site containing Y543. Isoleucine interaction
with this latter binding site is responsible for conformational modifications leading to final inhibition of
the enzyme. Y449 interacts with both regulators, isoleucine and valine. However, interaction of valine
with the high-affinity binding site induces different conformational modifications leading to reversal of
isoleucine binding and reversal of inhibition.
Biosynthetic threonine deaminase (EC 4.2.1.16; TD)1 is a
pyridoxal phosphate enzyme that catalyzes the deamination
of threonine into R-ketobutyrate.
Allosteric regulation of bacterial TD by its effectors
isoleucine and valine was studied initially in the pioneer
works of Umbarger (1) and Monod et al. (2). The kinetics
of the reaction were further investigated extensively using
an overproduced recombinant Escherichia coli enzyme (3-
9). E. coli TD exhibits sigmoidal substrate saturation behavior
in the absence of isoleucine. The feedback inhibitor isoleu-
cine decreases the affinity for threonine and increases the
cooperativity of the kinetics. On the other hand, valine
increases the affinity for threonine, decreases the degree of
cooperativity of the kinetics, and reverses the inhibition by
isoleucine.
The kinetics of the reaction catalyzed by TD have been
studied for various species, including bacteria (10-12), yeast
(13), and plants (14-16). The effect of isoleucine and valine
on these enzymes was shown to be similar to that described
for the E. coli enzyme. However, some differences exist at
the level of enzyme kinetics and the allosteric effect of
isoleucine. Indeed, in the absence of isoleucine, the yeast
(13) enzyme exhibits sigmoidal kinetics, similar to those of
the E. coli enzyme, whereas the Salmonella typhimurium
(11), Bacillus subtilis (10), and Spinacia oleracea enzymes
(15) show Michaelis-Menten behavior. Furthermore, the
yeast enzyme appears to be different from the other enzymes
in view of its activation by low concentrations of isoleucine
(13).
TD, like many pyridoxal phosphate enzymes, has been
shown to be stimulated by monovalent cations. The increase
in enzyme activity is particularly strong for plant TD, as
demonstrated for the spinach (15) or Paul’s scarlet rose
enzymes (14).
The bacterial enzyme is a homotetramer with a molecular
mass of 224 kDa. The resolution of the structure of the E.
coli enzyme crystallized without its effectors (17) clearly
demonstrated that each of the identical subunits is organized
into two different domains, in agreement with genetic studies
(4, 18) (Figure 1A). The N-terminal domain containing the
pyridoxal phosphate (PLP) cofactor was proposed to contain
the active site (Figure 1A). The C-terminal domain corre-
sponding to the regulatory domain is composed of two
homologous subdomains with 2-fold symmetry (Figure 1B).
As described in Figure 1A, the N- and C-terminal domains
constitute two globular domains connected by a helix and
there are no contacts between the domains within each
subunit (17). The tetramer of E. coli TD is a “dimer of
dimers” because only weak interactions, involving contacts
between catalytic domain, occur between both “dimers” (17).
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Thus, most of the interactions involved in the quaternary
structure take place between the regulatory domain of each
“dimer” (17).
A three-dimensional structure comparison between TD and
the allosteric enzyme D-3-phosphoglycerate dehydrogenase
(PGD) (19) disclosed that the regulatory domains of both
enzymes have similar folds (17). Indeed, two regulatory
domains of PGD associate with 2-fold symmetry to form a
dimeric regulatory domain which bears strong similarities
with the TD regulatory domain (Figure 1B) (17). Since PGD
has been cocrystallized with its regulatory effector serine
(19), and each dimeric regulatory domain interface of PGD
contains two symmetrical serine-binding sites, it is attractive
to make the hypothesis that TD could also possess two
effector-binding sites per regulatory domain. Additional
three-dimensional structure comparisons between E. coli TD
and PGD allowed us to determine several putative residues
of E. coli TD corresponding to those involved in the effector-
binding site of PGD. From these residues, only those
conserved among all the known TD amino acid sequences
were selected. At last, modeling of the Arabidopsis thaliana
regulatory domain using the Internet Swiss-Model server (20)
allowed us to determine that the orientation of the selected
residues is similar between the E. coli and A. thaliana TD.
These preliminary observations led us to make the hypothesis
that F352 and Y369 would be involved in one binding site
and that E442 and Y465 participate in a second binding site
of the E. coli TD (Figure 1B). In this paper, the importance
of these two tyrosines in the effector-binding site is
investigated in the A. thaliana enzyme.
To test the hypothesis that TD possesses two binding sites
per regulatory domain, we have overproduced and purified
the A. thaliana enzyme. Then, we have designed and
overproduced in E. coli two mutants of the enzyme in which
the two tyrosines, corresponding in A. thaliana to Y449 and
Y543, are modified. The wild-type and mutant enzymes were
further characterized by steady-state kinetics and equilibrium
binding experiments.
EXPERIMENTAL PROCEDURES
Materials. Restriction endonucleases were supplied by
New England Biolabs. Isopropyl â-D-thiogalactoside (IPTG)
was supplied by Boehringer (Meylan, France), and amino
acids were supplied by Sigma-Aldrich (Steinheim, Germany).
Oligonucleotides used for PCR amplification and site-
directed mutagenesis were obtained from Oligo Express
(Paris, France). Radioactive [3H]isoleucine and [3H]valine
were purchased from Amersham Pharmacia Biotech.
Strains. E. coli strain DH5R was used for cloning and
mutagenesis, while E. coli strain BL21pLysS was used for
recombinant protein overproduction.
Construction of the pET30TD Plasmid Encoding Mature
A. thaliana TD. The pET30TD plasmid encoding mature A.
thaliana threonine deaminase was constructed by PCR using
an A. thaliana (Wasilenski) cDNA bank with a proofreading
PWO polymerase. The oligonucleotide corresponding to the
coding sequence (21) was designed to have a NdeI restriction
site with insertion of an ATG codon instead of the codon
corresponding to the first amino acid (threonine 46) of the
putative mature A. thaliana sequence. The oligonucleotide
corresponding to the complementary sequence was con-
structed to insert a SalI restriction site after the TGA stop
codon. The PCR product was digested with NdeI and SalI
and cloned into a pET30a+ plasmid digested with NdeI and
SalI to give the pET30TD vector. Sequencing of the entire
insert was carried out, and the sequence was in complete
agreement with the previously described A. thaliana TD
sequence (21).
Site-Directed Mutagenesis. Site-directed mutagenesis were
carried out with the pET30TD vector and using the Quick-
Change Site-Directed Mutagenesis Kit (Stratagene). Oligo-
nucleotides were designed with replacement of tyrosine 449
or 543 with leucine and for modification of the restriction
enzyme profile for identification of mutants. Complete
sequencing of the mutants was also performed and showed
no mutations other than the desired ones.
Expression and Purification of the Wild-Type and Mutant
Enzymes. Transformed E. coli BL21pLysS cells were grown
at 28 °C in 750 mL of 2YT medium containing 100 mM
KH2/K2HPO4 (pH 7.5), 100 mM KCl, and the appropriate
antibiotics (34 íg/mL chloramphenicol and 50 íg/mL
kanamycin). IPTG was added to a final concentration of 0.5
mM when bacterial growth was equivalent to an A600 of 0.8.
Cells were further grown for 15 h at 28 °C and harvested by
FIGURE 1: Model of the E. coli TD (from ref 17). (A) The figure
shows a TD dimer ribbon model constituted by two equivalent
chains in dark and light gray. The N-terminal domain (N-ter)
containing the PLP cofactor (in CPK) was assigned as the active
site. The N- and C-terminal (C-ter) domains constitute two different
domains connected by a helix (17). (B) Regulatory domain of the
TD subunit. The residues of E. coli TD involved in the two effector-
binding sites were selected by structural comparison with PGD (19),
amino acid sequence comparison between known TD, and modeling
of the A. thaliana enzyme. Among these residues, we investigated
the importance of two symmetrical tyrosines (Y449 and Y543) of
the A. thaliana enzyme which correspond to Y369 and Y465 (in
sticks) of the TD E. coli enzyme, respectively.
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centrifugation at 2000g for 15 min. The pellet was resus-
pended in buffer A [50 mM Hepes (pH 7.5) and 1 mM
EDTA] containing protease inhibitors (5 mM ç-aminocaproic
acid and 1 mM benzamidine), 1 mM dithiothreitol (DTT),
and isoleucine. Wild-type and mutant TD were purified with
the same protocol except that isoleucine required for protein
stabilization was used in all purification steps at a concentra-
tion of 1 mM for the wild-type enzyme and 5 mM for mutant
enzymes. The cells were sonicated for 20 min at 0 °C on a
Vibra-cell disruptor. Following centrifugation at 28000g for
30 min, the pellet was discarded and the supernatant was
applied to a Fractogel DEAE EMD 650 column (2.6 cm 
30 cm) (Sigma) equilibrated in buffer A. Elution was
performed with a 800 mL gradient of 0 to 400 mM KCl in
buffer A containing isoleucine. Chromatographic fractions
containing threonine deaminase activity were eluted at 300
mM KCl. These fractions were concentrated on a Macrosep
30K concentrator (Filtron) and applied to a HiLoad 26/60
Superdex 200 column (Pharmacia Biotech) previously equili-
brated with buffer A containing isoleucine. After elution,
threonine deaminase activity was concentrated on a Macrosep
30K concentrator and then applied to a HiLoad 16/10
Q-Sepharose column (Pharmacia Biotech) equilibrated in
buffer A. Elution was performed with a 400 mL gradient of
0 to 400 mM KCl in buffer A containing isoleucine.
Threonine deaminase activity was eluted at 200 mM KCl.
The enzyme was further concentrated on a Microsep 30K
concentrator (Filtron) to a concentration of 30 mg/mL and
stored at -80 °C for several months without any loss of
activity.
Electrophoresis and Protein Quantitation. SDS-PAGE
was performed according to the method of Chua (22). The
protein was quantitated either by the method of Bradford
(23) (for crude extracts only) with bovine ç-globulin as a
standard or by measuring A205 as described by Scopes (24).
Protein-PLP Stoichiometry. Knowing the amino acid
composition of the A. thaliana TD, we have carried out
accurate determination of protein concentration and protein-
PLP stoichiometry using the molar extinction coefficients
of tyrosine, tryptophan, and PLP under alkaline conditions
(0.1 M NaOH) as described previously for threonine synthase
(25).
In Vitro Assays of TD. Threonine deaminase activity was
assayed in 100 mM KH2/K2HPO4 (pH 8.0) in a final volume
of 1 mL. Reactions were initiated by adding threonine (0-
40 mM) without or with isoleucine (0-20 mM) and valine
(0-20 mM). All stock solutions of amino acids were
prepared in 100 mM KH2/K2HPO4 (pH 8.0). The progress
of the reaction was monitored by the increase in absorbance
at 230 nm due to R-ketobutyrate. Enzyme activity was
expressed as micromoles of R-ketobutyrate produced per
minute per milligram of protein using an  of 536 mol-1
cm-1.
Filtration Binding Assay. Experiments were carried out
with a method adapted from those described earlier (26) for
the binding of S-adenosylmethionine to ribonucleotide re-
ductase. For each measurement, 0.6-1 mg of TD was
incubated in 10 mL of 100 mM KH2/K2HPO4 buffer (pH
8.0) containing various concentrations of isoleucine or valine
(5-300 íM) and 2-5 íL of radiolabeled effector (87.0 Ci/
mmol of L-[4,5-3H]isoleucine or 23.0 Ci/mmol of L-[3,4-
3H]valine). Experiments with radioactive isoleucine or valine
concentrations of >300 íM were not possible under our
experimental conditions since the level of nonspecific binding
became too high. After incubation of TD (30 min at 25 °C)
with different effector concentrations, 10 mL of TD was
separated in three parts of 3 mL each. The remaining volume
of 1 mL was used for determination of the amount of total
radioactivity. The three incubation mixtures of 3 mL were
filtered under vacuum (25 mmHg) on VMWP filters with a
0.05 ím pore size (Millipore) inserted on a vacuum filtration
unit (Hoefer Scientific Instrument). After filtration, filters
were dried at room temperature on Benchkote (Whatman)
and the amount of radioactivity was determined in a vial
using 8 mL of Ready Protein scintillation liquid. In parallel,
measurements of controls using BSA instead of TD were
also carried out in triplicate at identical buffer, ligand, and
protein concentrations and subtracted from the amount of
radioactivity of TD samples. The difference between TD and
BSA filters was compared to the amount of total radioactivity
determined from the unfiltered reaction assays and used to
determine the stoichiometry of effector binding. Typically,
at 105 íM isoleucine (1918 dpm/nmol of isoleucine) and
with 5 nmol of wild-type TD (on a monomeric basis; in 3
mL of binding buffer), a difference of about 18 000 dpm
can be determined after subtraction of the amount of
radioactivity bound to BSA filters from that bound to TD
filters. Other assays, using threonine synthase [a PLP enzyme
purified in our laboratory (25)] as controls, gave the same
results as those obtained with BSA. For reversal of isoleucine
binding by valine, the protein was first incubated for 5 min
with 100 íM isoleucine and radiolabeled isoleucine. Then,
various concentrations (0-15 mM) of nonradioactive valine
were added, and incubation was continued for 30 min at 25
°C.
Kinetic Data Analyses. Kinetic data were fitted with the
appropriate theoretical equations by using the KaleidaGraph
program (Abelbeck Software).
Structure Analyses. Stucture analyses of E. coli PGD and
TD PDB files were carried out with the WebLab ViewerPro
program (Molecular Simulations Inc.). Modeling of the A.
thaliana sequence was carried out using the Internet Swiss-
Model server (20).
RESULTS
OVerproduction and Purification of Wild-Type and Mutant
A. thaliana TD. To obtain a mature protein without its transit
peptide, we determined the putative cleavage site of A.
thaliana TD by homology with the Lycopersicon esculentum
enzyme for which the N-terminal amino acid sequence has
been reported (27). Expression of a sequence beginning at
amino acid 46 (putative cleavage site) yielded production
of high amounts of soluble protein. Lengthening the sequence
(including the entire peptide transit) or shortening the
sequence (beginning at amino acid 71) resulted in production
of the insoluble protein. The mutant and wild-type enzymes
were purified following a protocol identical to that docu-
mented in Figure 2 and described in Experimental Proce-
dures. Typically, a culture of 750 mL allowed us to obtain
17 mg of pure enzyme.
As Figure 2 shows, the recombinant A. thaliana enzyme
is composed of 59 800 Da subunits. Gel filtration experi-
ments carried out on Superdex 200 in the absence of
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isoleucine indicated that the wild-type enzyme behaves as a
tetramer under our experimental conditions (not shown). The
PLP content determined for the wild-type TD showed a
stoichiometry of 1 mol of PLP per monomer. The recom-
binant enzyme was strongly activated by monovalent cations
such as K+, Li+, NH4+, and Na+ with an increase of activity
of 3.0-, 2.8-, 2.1-, and 1.7-fold, respectively. The activation
curves followed hyperbolic behavior, and the K0.5 value of
activation for the most active monovalent cation (K+) was
determined to be 3.1 mM. In contrast, bivalent cations such
as Mg2+ or Ca2+ led to inhibition of enzyme activity by a
factor of 3.0 or 3.2, respectively. Optimum activity was found
at pH 8.0 in 100 mM KH2/K2HPO4. In this buffer containing
a saturating threonine concentration (40 mM) and at 25 °C,
the specific activity of the purified wild-type TD was 400
ímol min-1 (mg of protein)-1. Mutants Y449L and Y543L
exhibited the same physicochemical and catalytic properties
as those determined for the wild-type enzyme with respect
to molecular mass, PLP content, cation requirement, optimum
pH, and specific activity.
Kinetic EVidence for Two Different Effector-Binding Sites.
In the absence of isoleucine, the threonine saturation curve
followed Michaelis-Menten behavior for the wild-type and
both mutant enzymes. Furthermore, Y449L and Y543L
mutants displayed a specific activity [400 ímol min-1 (mg
of protein)-1] and an apparent KM for threonine (7.9 mM)
nearly identical to those determined for the wild-type enzyme
(Figure 3), indicating that mutation of Y449 and Y543 has
no effect on the catalytic domain. In the presence of
isoleucine, substrate kinetics became sigmoidal and the K0.5
value for threonine was increased for the wild-type and
mutant enzymes (Figure 3) compared to the KM value
determined in the absence of isoleucine. However, the
concentration of isoleucine required for enzyme inhibition
was much higher for the two mutants than for the wild-type
enzyme (Figures 3 and 4).
Inhibition by isoleucine of Y449L and Y543L mutants was
strongly altered compared to that of the wild-type enzyme
(Figure 4). Indeed, the concentration of isoleucine needed
to reach 50% inhibition of activity of mutants Y449L and
FIGURE 2: Documentation of the purification procedure for the wild-
type A. thaliana TD by SDS-PAGE. Proteins were separated on
a 10% polyacrylamide (w/v) slab gel under denaturing conditions
and stained with Coomassie Brillant Blue R250: lane 1, Mr markers;
lane 2, soluble proteins of the E. coli crude extract (30 íg); lane 3,
EMD DEAE 650 (M) pool (20 íg); lane 4, S200 pool (10 íg); and
lane 5, Q-Sepharose pool (5 íg). An identical procedure was used
to purify Y449L and Y543L.
FIGURE 3: Steady-state kinetics of wild-type TD and the Y449L
and Y543L mutants. Assays were carried out without effector (open
symbols) or with isoleucine (filled symbols). Vmax corresponds to
400 ímol min-1 mg-1. The isoleucine concentrations used in this
experiment are close to the K0.5 values for isoleucine determined
in Figure 4 (for the WT, 70 íM; for the Y449L and Y543L mutants,
2.5 mM). The data corresponding to the assays carried out without
effector were fitted by an hyperbolic equation [WT, KM(threonine)
) 7.64 ( 0.40 mM; Y449L, KM(threonine) ) 7.96 ( 0.42 mM;
and Y543L, KM(threonine) ) 7.99 ( 0.56 mM]. Data corresponding
to the assays carried out with isoleucine were fitted by a Hill
equation [WT, K0.5(threonine) ) 37.79 ( 1.24 mM and nH ) 2.19
( 0.10; Y449L, K0.5(threonine) ) 31.18 ( 0.71 mM and nH )
2.89 ( 0.15; and Y543L, K0.5(threonine) ) 36.63 ( 2.45 and nH
) 2.04 ( 0.18].
FIGURE 4: Effect of isoleucine on the activity of wild-type TD and
the Y449L and Y543L mutants. Reactions were monitored in buffer
containing 40 mM threonine. The data corresponding to mutant
Y543L were fitted with a Hill equation [K0.5(inhibition) ) 2.42 (
0.19 mM and nH ) 1.44 ( 0.10]. Data corresponding to the wild-
type enzyme and mutant Y449L were fitted with a hyperbolic
equation followed by a Hill equation as described below: inhibition
% ) [(-VaS)/(K0.5act + S)] + [(ViSnH)/(K0.5inhib + SnH)], where Va
and Vi are the maximal level of activation and inhibition, respec-
tively, and S is the concentration of isoleucine [WT, K0.5(activation)
) 2.81 ( 4.51 íM, K0.5(inhibition) ) 64.18 ( 0.98 íM, and nH )
2.19 ( 0.06; and mutant Y449L, K0.5(activation) ) 0.31 ( 0.13
mM, K0.5(inhibition) ) 2.94 ( 0.04 mM, and nH ) 3.06 ( 0.12].
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Y543L has been increased by a factor 45 and 38, respectively
(Figure 4). As shown in Figure 4 (inset), the plot of the extent
of inhibition of the wild-type enzyme as a function of the
concentration of isoleucine exhibited two components. A first
decreasing curve (activation) defining a site of high affinity
for isoleucine was followed by a second increasing curve
(inhibition) defining a second site of lower isoleucine affinity.
Thus, the wild-type A. thaliana TD is activated at low
isoleucine concentrations (0-10 íM). On the other hand,
higher isoleucine concentrations led to inhibition of the wild-
type enzyme. This behavior prevented us from fitting the
curve with a classical Hill equation. However, we attempted
to fit the curve by the sum of a hyperbolic equation and a
Hill equation to account for activation and inhibition of
enzyme activity, respectively. This sequential equation did
not allow us to accurately determine the K0.5 value for
activation (less than 5 íM) but gave a good estimate of the
K0.5 for inhibition with a value of 64 íM (determined with
a saturating threonine concentration of 40 mM). Interestingly,
Y449L and Y543L mutants exhibited different behaviors
with respect to isoleucine concentration. As described in
Figure 4, the mutant Y449L showed more clearly the
phenomenon of activation by isoleucine, but at a higher range
of isoleucine concentrations (up to 500 íM) compared to
the wild-type enzyme. Isoleucine concentrations of >1 mM
led to inhibition of Y449L. Use of the sequential equation
described above allowed us to determine a K0.5 values for
activation and inhibition of 0.31 and 2.94 mM, respectively
(values determined with 40 mM threonine) (Figure 4). In
contrast, mutant Y543L did not show any activation at low
isoleucine concentrations. Moreover, this mutant was inhib-
ited at slightly lower isoleucine concentrations than mutant
Y449L, with a K0.5 value of 2.42 mM (determined at 40 mM
threonine) (Figure 4).
As demonstrated in Figure 5, the inhibition of the wild-
type enzyme by isoleucine can be reversed by valine.
Reversal of inhibition can be fitted with a hyperbolic equation
yielding a K0.5 for reactivation of the enzyme by valine of
0.79 mM (in the presence of 70 íM isoleucine). Mutants
Y449L and Y543L exhibited different behaviors with respect
to valine. Indeed, inhibition of mutant Y449L by isoleucine
can be reversed by addition of valine (K0.5 of 1.47 mM for
valine for reactivation in the presence of 3 mM isoleucine;
see Figure 5), whereas mutant Y543L became insensitive to
valine over the range of valine concentrations that were tested
(e3 mM).
The different behaviors observed with mutants Y449L and
Y543L at the level of isoleucine activation and reversal of
isoleucine inhibition by valine strongly indicate that A.
thaliana TD contains two different effector-binding sites. To
determine the effector specificity of both binding sites, we
carried out equilibrium binding experiments with the wild-
type and mutant enzymes.
Isoleucine Binding to the Wild-Type and Mutant Enzymes.
Binding experiments with [3H]isoleucine carried out with the
wild-type enzyme clearly confirmed the existence of two
isoleucine-binding sites per A. thaliana TD subunit (Figure
6). Indeed, the best fit of isoleucine binding data with the
wild-type enzyme was achieved by using a Hill equation,
which allowed us to determine the saturation of two binding
sites with a K0.5 value of 16.5 íM and a slight positive
cooperativity (nH ) 1.3). In marked contrast, isoleucine
binding to mutants Y449L and Y543L was greatly altered
(Figure 6). Indeed, at isoleucine concentrations of <200 íM,
saturation isotherms showed that mutant Y543L was able to
bind 1 mol of isoleucine per monomer only. In this case,
the best fit of the isoleucine binding data was achieved by
using a hyperbolic equation yieding a Kd value of 7.0 íM.
Isoleucine binding to mutant Y449L was altered differently.
As Figure 6 shows, no saturation could be reached in the
isoleucine range investigated herein (e200 íM isoleucine),
suggesting that mutant Y449L remains able to bind isoleucine
but with a much lower affinity than the wild-type enzyme
and mutant Y543L. In summary, these equilibrium binding
experiments demonstrated the existence of two isoleucine
binding sites per monomer. Moreover, these results demon-
strate that only one of these sites has been altered in mutant
Y543L, whereas two sites were affected in mutant Y449L.
Valine Binding to the Wild-Type and Mutant Enzymes.
Filtration binding experiments using valine with the wild-
type and mutant Y543L enzymes gave similar results, with
a saturation at 0.5 mol of valine per monomer at valine
concentrations of <200 íM (Figure 7). In each case, the
best fit of the binding data was achieved by using a
hyperbolic equation leading to the determination of a Kd
FIGURE 5: Reversal of isoleucine inhibition by valine on wild-
type TD and mutant Y449L. Assays were carried out at isoleucine
concentrations close to the K0.5 values for isoleucine (for the WT
enzyme, 70 íM; and for the mutant Y449L, 3 mM) (Figure 4).
Reactions were monitored in buffer containing 20 mM threonine.
Vmax values were determined in buffer without isoleucine. The data
were fitted with a hyperbolic equation for the WT enzyme [K0.5-
(valine) ) 0.79 ( 0.08 mM] and for mutant Y449L [K0.5(valine)
) 1.47 ( 0.21 mM].
FIGURE 6: Isoleucine binding to wild-type TD and the Y449L and
Y543L mutants. Data corresponding to the assays carried out with
the wild-type enzyme were fitted by a Hill equation [K0.5(isoleucine)
) 16.51 ( 1.06 íM and nH ) 1.26 ( 0.08]. Data corresponding
to the assays carried out with Y543L were fitted with a hyperbolic
equation [Kd(isoleucine) ) 7.03 ( 0.79 íM].
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value of 12 and 24 íM for the wild-type and mutant Y543L
enzymes, respectively. In contrast and as shown in Figure
7, mutant Y449L became unable to bind valine. These results
demonstrate that Y543L is able to bind low valine concentra-
tions, whereas Y449L has lost this ability. To understand
the effect of valine on the reversal of inhibition and on the
binding of isoleucine, we carried out further equilibrium
binding experiments to follow reversal of isoleucine binding
by valine.
ReVersal of Isoleucine Binding by Valine. Reversal of
isoleucine binding was investigated with a fixed radioactive
isoleucine concentration of 100 íM and with increasing
concentrations of nonradioactive valine. Displacement of the
small amount of isoleucine (0.1 mol per monomer) bound
to Y449L was completely achieved with 1 mM valine (not
shown). As shown in Figure 8, the reversal of bound
isoleucine from the wild-type TD and from mutant Y543L
by valine can be fitted with a hyperbolic equation, allowing
the determination of Kd values of 2.5 and 0.17 mM,
respectively. Using this equation, the estimated value for the
remaining isoleucine, at saturing valine concentrations, on
the wild-type enzyme and Y543L was 0.1 and 0.07 mol of
isoleucine per monomer, respectively, suggesting that valine
binding led to almost complete reversal of isoleucine from
the two binding sites.
DISCUSSION
The purified recombinant A. thaliana TD exhibits a
specific activity of 400 ímol min-1 mg-1 (at 25 °C), higher
than that determined for the recombinant E. coli enzyme (210
ímol min-1 mg-1 at 20 °C) (3). As described for the other
plant enzymes previously studied (14, 15), A. thaliana TD
has a strong requirement for monovalent cations and in
particular for K+ which was found to stimulate the enzyme
by about 3-fold. The purified recombinant A. thaliana TD
obeys Michaelis-Menten kinetics in the absence of isoleu-
cine as described for A. thaliana desalted crude extract (16)
and for S. typhimurium (11), B. subtilis (10), and S. oleracea
purified enzymes (14). This behavior is different from that
established for the E. coli (3) and Saccharomyces cereVisiae
(13) enzymes, which exhibit sigmoidal kinetics in the absence
of isoleucine.
A three-dimensional structure comparison between the E.
coli TD (17) and PGD (19) showed that the dimeric
regulatory domain of PGD bears strong similarities to the
regulatory domain of TD (17). Since the interface of each
dimeric regulatory domain of PGD contains two serine
binding sites (19, 28, 29), we can imagine that TD could
also possess two effector-binding sites per regulatory domain.
A careful three-dimensional structure comparison between
E. coli TD and PGD allows us to identify several putative
residues of E. coli TD corresponding to the effector-binding
site of PGD. Among these amino acids, only those conserved
among bacterial, fungal, and plant TD amino acid sequences
were further selected. These preliminary observations indi-
cated that F352 and Y369 would be involved in one binding
site and that E442 and Y465 participate in the second binding
site of the E. coli TD (Figure 1). Further observations allow
us to determine that the conformation of these four amino
acids is similar between the E. coli and A. thaliana TD as
shown by the comparison of the structure of the bacterial
enzyme and modeling of the A. thaliana enzyme (20; Internet
Swiss-Model program, not shown). In this paper, we
determined the importance of the corresponding A. thaliana
Y449 and Y543 in the mechanism of regulation of plant TD.
Previous studies with double (residues 447 and 451) and
triple (residues 447, 451, and 454) mutants were carried out
on a helix belonging to one subdomain of the regulatory
domain of E. coli TD (9). These double and triple mutants
are less sensitive to both effectors with decreases in isoleu-
cine affinity of about 15- and 100-fold, respectively (9).
However, these mutations have also decreased the affinity
for threonine in the absence of isoleucine (9). This observa-
tion suggests therefore that these mutations have also induced
modification of conformations at the level of the active site
leading to enzyme inhibition. In contrast to these experi-
ments, single mutations at Y449 and Y543 of the A. thaliana
enzyme led to a strong decrease in isoleucine affinity without
altering the kinetics with respect to threonine in the absence
of effector.
Kinetic measurements of isoleucine and valine regulation
on Y449L and Y543L mutants demonstrate for the first time
that A. thaliana TD has two structurally different allosteric
effector-binding sites per monomer. Indeed, our results
clearly show that mutation of either Y449 or Y543 leads to
a dramatic decrease in the level of enzyme inhibition by
isoleucine since the K0.5 values of this effector for both
mutants are increased by about 40-fold compared to that of
the wild-type enzyme (Figure 4). Furthermore, our results
demonstrate that these two sites exhibit different features
with respect to valine and isoleucine. Indeed, mutant Y543L
is not activated by low concentrations of isoleucine, whereas
mutant Y449L is activated by higher isoleucine concentra-
tions than the wild-type enzyme (Figure 4). In addition,
isoleucine inhibition of mutant Y449L can be reversed by
valine (Figure 5), whereas mutant Y543L became insensitive
to valine reversal (not shown).
FIGURE 7: Valine binding to wild-type TD and Y543L mutants.
Data were fitted with a hyperbolic equation for the wild type [Kd-
(valine) ) 12.65 ( 1.37 íM] and mutant Y543L [Kd(valine) )
24.47 ( 5.27 íM].
FIGURE 8: Reversal of isoleucine binding to wild-type TD and
mutant Y543L by valine. Data were fitted with a hyperbolic
equation for the wild-type enzyme [Kd(valine) ) 2.57 ( 0.17 mM]
and for mutant Y543L [Kd(valine) ) 171.63 ( 3.94 íM].
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Observations of the effect of isoleucine on the wild-type
enzyme led to the hypothesis that one of the two binding
sites would correspond to a high-affinity binding site for
isoleucine (Figure 4, inset). One hypothesis is that isoleucine
binding at this high-affinity site would induce a modification
of the conformation at the level of the catalytic domain which
leads to a conformer exhibiting higher activity. At the same
time, isoleucine binding in this high-affinity site would also
induce a modification of the conformation at the level of
the regulatory domain, allowing the second binding site with
lower affinity to interact with a second isoleucine. Finally,
the binding of this second isoleucine would lead to a second
modification of the conformation in the catalytic domain,
leading to the observed inhibition.
Our results indicate that mutation of Y449 altered dramati-
cally the concentration needed for isoleucine activation
(Figure 4), suggesting that Y449 would belong to the high-
affinity isoleucine-binding site. However, since mutation of
Y543 suppresses completely the activation by isoleucine
(Figure 4), Y543 could be also involved in this high-affinity
isoleucine-binding site. To distinguish between these two
hypotheses, filtration binding experiments were further
carried out to determine the effector specificity of both
binding sites.
Our filtration binding experiments with isoleucine and the
wild-type enzyme have demonstrated definitively the binding
of 2 mol of isoleucine per monomer, in agreement with the
structural comparison and our kinetic results. Binding
experiments with isoleucine and mutants Y449L and Y543L
showed that mutations have altered in a different way the
binding of isoleucine. Our experiments showed that each
monomer of mutant Y543L is able to bind 1 mol of
isoleucine with a Kd similar of those determined for the wild-
type enzyme. This observation suggests that the unaffected
site of Y543L (Y449) can always binds with high affinity 1
mol of isoleucine. It must be pointed out that the binding of
isoleucine to mutant Y543L is reached at a concentration
100-fold lower than those required for inhibition (Figures 4
and 6). This latter result suggests, therefore, that binding of
isoleucine to Y449 is not responsible for the observed
inhibition. Furthermore, this result is in agreement with the
hypothesis that Y449 belongs effectively to the high-affinity
site for isoleucine. Filtration binding experiments carried out
on mutant Y449L indicated that this mutant is always able
to bind isoleucine but with a much lower affinity (Figure
6). Once again, this result is in accordance with the
hypothesis that Y449 belongs to the high-affinity site for
isoleucine since mutation of Y449 increases the isoleucine
concentration needed to fill this site and thus the concentra-
tion required to induce modification of the conformation
leading to the binding of isoleucine to the other site.
Filtration binding experiments carried out with valine had
showed that the wild-type enzyme and mutant Y543L bind
in a similar way 1 mol of valine per two monomers,
demonstrating that Y449 is also involved in the binding of
valine. In agreement with this finding, no binding of valine
has been detected for mutant Y449L (Figure 7). Thus, our
results show that the high-affinity binding site for isoleucine
is also able to interact with valine on the wild-type enzyme.
One hypothesis is that valine competes with isoleucine for
interaction with Y449. However, binding of valine to Y449
could lead to a conformational modification, different from
those induced by isoleucine and preventing the binding of
the second isoleucine to Y543. Such a hypothesis is
supported by the reversibility of isoleucine binding (Figure
8) and reversal of inhibition (Figure 5) upon addition of
valine.
Filtration binding experiments with isoleucine and the
wild-type enzyme led to the saturation of two binding sites
per monomer (Figure 6), whereas experiments carried out
with valine allow saturation of only one binding site per
dimer (one-half per monomer) (Figure 7). This result is
another indication that valine and isoleucine binding leads
to different modifications of conformation. Indeed, binding
of 2 mol of isoleucine to one monomer does not prevent the
binding of an additional 6 mol of isoleucine to the three other
monomers belonging to the tetramer. However, binding of
2 mol of valine to A. thaliana TD would display strong
negative cooperativity. In this case, binding of valine to two
monomers would induce conformational modifications that
prevent the binding of valine to the two other monomers of
the tetramer.
In conclusion, the results of kinetic and binding experi-
ments allow us to propose a new working model for the
interaction between the effector-binding sites and their effect
on the regulation of activity. Our model states that each
regulatory domain of each monomer constituting the native
tetramer of A. thaliana TD possesses two effector-binding
sites corresponding to Y449 and Y543 (Figure 9). Our model
suggests that Y449 belongs to a high-affinity binding site
whose interaction with isoleucine leads to conformational
FIGURE 9: Working model to account for the interactions of
isoleucine with the two binding sites of each regulatory domain of
A. thaliana TD (see the text): (A) wild-type enzyme, (B) mutant
Y449L, and (C) mutant Y543L. Open circles correspond to a
regulatory domain (see Figure 1). White triangles correspond to
low isoleucine concentrations. Dark triangles correspond to high
isoleucine concentrations. Asterisks correspond to a conformer
exhibiting higher activity upon binding of 1 mol of isoleucine per
monomer. Binding of 2 mol of isoleucine (I-I) per monomer leads
to inhibition of enzyme activity. For mutant Y543L, discontinuous
lines between the two regulatory sites indicate that the site
corresponding to Y543 has lost its ability to undergo a conforma-
tional change upon binding of isoleucine to Y449. The site
containing Y449 behaves also as a binding site for valine. The effect
of valine is described in the text only.
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modifications corresponding to a conformer displaying a
higher activity. This conformation is able to bind more
efficiently isoleucine on a second lower-affinity binding site
containing Y543. Isoleucine interaction with Y543 is re-
sponsible of conformational modifications leading to final
inhibition of the enzyme (Figure 9). Y449 of the wild-type
enzyme interacts with both regulators, isoleucine and valine.
However, interaction of valine with Y449 induces different
conformational modifications leading to reversal of isoleucine
binding and reversal of inhibition.
Mutant Y543L shows no activation at low isoleucine
concentrations (Figure 4), and there is no effect of valine
on the reversal of isoleucine inhibition. To explain this
behavior, we have to introduce in our model the idea that
mutation at Y543 has also altered the transfer of information
between the two binding sites. In other words, upon binding
of isoleucine to the high-affinity binding site, mutant Y543L
has lost its ability to undergo a modification of the
conformation leading to a conformer exhibiting a higher
activity and a better affinity for the second isoleucine. Thus,
in mutant Y543L, the alteration of the communication
between Y543 and Y449 would also alter the ability of valine
to reverse isoleucine inhibition without affecting the binding
of valine on Y449.
Finally, this work demonstrates that the sequential binding
of two isoleucines inside each regulatory domain of the A.
thaliana TD induces modification of the conformation of
the catalytic domains leading to inhibition of activity. In
addition to this mechanism, our results also indicate that
regulation of plant TD activity arises from interactions
between subunits as shown by cooperativity at the level of
ligand binding and threonine kinetic. Despite the differences
observed between the plant and bacterial enzymes, this study
does not rule out the mechanism of allosteric regulation
established for the E. coli TD (2). However, our paper shows
that the mechanism of regulation of the plant TD is different
and more complicated than that postulated by previous
studies (2) on the bacterial enzyme. At this step, cocrystal-
lization of the plant and bacterial TD with the effectors valine
and isoleucine will help in understanding the regulation of
these complexes.
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